Zyprexa Goes Generic: Teva Fills "Basket" Of Doses With Dr. Reddy's Deal
Teva Pharmaceutical Industries greeted the patent expiration of Lilly’s Zyprexa (olanzapine) by launching all six tablet doses of the antipsychotic, thanks to an agreement with Dr. Reddy’s Laboratories Ltd.
You may also be interested in...
The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.
Lilly's earnings are in line with analyst expectations, but higher costs cut into profits as the company prepares for a revenue decline.